Stock Research Monitor: AZN, CPHI, and MRK

LONDON, UK / ACCESSWIRE / May 15, 2018/ If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com recalls the recent performance of four Major Drug Manufacturers, particularly: AstraZeneca PLC (NYSE: AZN), China Pharma Holdings Inc. (NYSE AMER: CPHI), Pfizer Inc. (NYSE: PFE), and Merck & Co. Inc. (NYSE: MRK). Companies in this industry manufacture and process pharmaceutical products. Key areas of development include cardiovascular, cancer, and diabetes medications, as increases in the number of elderly and obese patients fuel disease growth in these categories. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

AstraZeneca

Cambridge, the UK headquartered AstraZeneca PLC's stock finished Monday's session 0.05% higher at $36.42 with a total trading volume of 3.36 million shares. Over the last month and the previous three months, the Company's shares have advanced 0.28% and 6.83%, respectively. Additionally, the stock has gained 7.12% over the past year. Shares of the Company are trading above their 50-day and 200-day moving averages by 3.72% and 8.28%, respectively. Moreover, shares of AstraZeneca, which discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide, have a Relative Strength Index (RSI) of 60.99. Get the full research report on AZN for free by clicking below at:

www.wallstequities.com/registration/?symbol=AZN


China Pharma Holdings

Shares in Haikou, China headquartered China Pharma Holdings Inc. jumped 4.49%, ending yesterday's session at $0.28 with a total trading volume of 139,404 shares. The stock has gained 28.84% over the past year. The Company's shares are trading 10.81% above their 200-day moving average. Moreover, shares of China Pharma, which develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in China, stock has an RSI of 45.51.

On May 08th, 2018, China Pharma announced that it plans to hold its Q1 2018 earnings conference call on May 15th, 2018, at 8:30 a.m. ET. Find your free research report on CPHI at:


www.wallstequities.com/registration/?symbol=CPHI


Pfizer

On Monday, New York headquartered Pfizer Inc.'s stock rose 1.01%, to close the day at $35.86. A total volume of 20.16 million shares was traded. The Company's shares have advanced 3.46% in the previous three months and 8.63% over the past year. The stock is trading 0.76% above its 200-day moving average. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 50.49.

On April 26th, 2018, Pfizer's Board of Directors declared Q2 2018 dividend of $0.34 on the Company's common stock, payable on June 01st, 2018, to shareholders of record at the close of business on May 11th, 2018. Sign up today for the free research report on PFE at:

www.wallstequities.com/registration/?symbol=PFE

Merck

Shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. ended the day 0.02% lower at $59.68. A total volume of 9.44 million shares was traded. The stock has gained 4.39% in the last month and 7.67% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 5.90% and 1.39%, respectively. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 61.60.

On April 23rd, 2018, research firm Goldman upgraded the Company's stock rating from ?Neutral' to ?Buy'.

On May 01st, 2018, Merck, known as MSD outside the US and Canada, announced its results for Q1 2018. Worldwide sales were $10.0 billion for the quarter, GAAP earnings per share were $0.27, and gross margin was 68.3%. Marketing and administrative expenses were $2.5 billion for Q1 2018, and R&D expenses were $3.2 billion. Wall St. Equities' research coverage also includes the downloadable free report on MRK at:

www.wallstequities.com/registration/?symbol=MRK

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities